Senate Report Backs Dental Industry Views On Red Tape
30th Apr 18
A Senate Committee has accepted advice from the Australian Dental Industry Association (ADIA) that although the Australian Government has a strong track-record of reducing red-tape in the healthcare sector there remains considerable scope for continued reform.
Key Issues For The Dental Industry —
The Senate inquiry reviewing the effect of red-tape in the healthcare sector has drawn heavily upon advice from ADIA about the need for ongoing reform to reduce burdensome and duplicative red-tape on not only the dental industry, but the therapeutic goods sector more broadly.
As the peak business organisation representing innovative dental product manufacturers and suppliers, ADIA was invited to tender a submission to the inquiry and appear before Senators at a hearing in Parliament House to tender advice as to how red-tape impeded the ability of businesses in the dental industry to grow, create jobs and operate sustainably.
The resulting report from the Senate red-tape committee has drawn heavily upon the advice and recommendations provided by ADIA, particularly in the following areas:
Teeth Whitening Product Regulation ―
The Senate committee considered ADIA’s concerns with the Australian Competition and Consumer Commission’s (ACCC) involvement in the regulation of teeth whitening products that creates regulatory inconsistencies and compliance challenges as state / territory governments already regulate such products. The Senate noted that the regulatory inconsistency raised by ADIA has now been addressed, with the ACCC having withdrawn its public guidance on the supply of teeth whitening products.
CBCT / CBVT Ownership ―
The Senate committee paid particular interest to ADIA's reference to state / territory government licensing requirements that affect businesses which supply, own and operate diagnostic imaging equipment. The Senate accepted advice from ADIA that regulatory variation creates a compliance burden for suppliers and healthcare professionals. This produced a specific recommendation that the Australian Government place licensing requirements for the supply, ownership and operation of diagnostic imaging equipment on the agenda for consideration by the Council of Australian Governments (COAG).
The committee concluded that the Australian Government's deregulation agenda in 2013 which aims to reduce excessive, unnecessary and complex regulation to lift productivity and boost growth continues to enjoy support; however, there remains areas in which red tape continues to affect health services.
ADIA is supportive of the Senate Committee’s view, as set out in the report, that duplicative / inconsistent regulation should be avoided as it creates unnecessary red-tape burdens. Similarly, ADIA endorses the views of the Senate committee that notes that the regulatory reform agenda requires a whole-of-government effort toward red tape reduction. In fulfilling this agenda, the Senate committee encouraged all departments and agencies to be aware not just of their regulatory environment but also those with which they interact.
Following the release of the Senate Committee’s report ADIA has continued its policy advocacy to progress the committee’s recommendations.
Member Engagement —
On matters associated with dental product regulation the policy advocacy team within the ADIA National Office receive advice and guidance from members serving on the ADIA-PRPC Product Regulation Policy Committee. Frequent updates are provided to members that attend the quarterly series of ADIA State Branch Briefings.
Further Information —
For further information on ADIA's efforts to reduce red-tape in the medical devices sector send an email to firstname.lastname@example.org or telephone 1300 943 094. To keep up to date follow ADIA on Facebook at www.facebook.com/dental.industry or subscribe to the Twitter feed @AusDental.
Currency Of Information & Disclaimer —
This update was issued on 30 April 2018 and please note that changes in circumstances after the publication of material or information may impact upon its accuracy and also change regulatory compliance obligations. The statements, regulatory and technical information contained herein are believed to be accurate and are provided for information purposes only. Readers are responsible for assessing its relevance and verifying the accuracy of the content. To the fullest extent permitted by law, ADIA will not be liable for any loss, damage, cost or expense incurred in relation to or arising as a result of relying on the information presented here.
This information is available for your use under a Creative Commons Attribution 3.0 Australia licence, with the exception of the ADIA logo, other images and where otherwise stated.
|A —.. A D I A . .S T R A T G E G I C . .A L L I A N C E S
|* To access this file you will need to log into your ADIA Member Plus Account.
...To get your member details email email@example.com
1st Jul 19
On Thursday, 20 June 2019, the ADIA held its first Technical Forum by teleconference. The Forum is a place where companies that are having any regulatory or technical issues (not just TGA issues) can come together and discuss the issue
10th Sep 19
The Therapeutic Goods Administration (TGA), in consultation with consumer, health professional and pharmaceutical industry representatives, has developed an improved template for Consumer Medicine Information (CMI).